KPV

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

KPV — α-MSH-Derived Anti-Inflammatory Tripeptide

KPV is a synthetic tripeptide composed of three amino acids — Lysine (K), Proline (P), and Valine (V) — derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide produced by the pituitary gland. Though KPV represents only a small fragment of its parent hormone, it retains potent anti-inflammatory activity while shedding α-MSH’s broader hormonal effects, including melanotropic (pigmentation) activity. This makes KPV a mechanistically clean and chemically stable compound, and a subject of growing scientific interest in the study of inflammation, intestinal barrier integrity, wound healing, and immune modulation.

Why KPV’s Mechanism Stands Apart

Most anti-inflammatory compounds — including steroids and NSAIDs — work by broadly suppressing immune function, which introduces well-documented tradeoffs. KPV operates differently. Rather than shutting the immune system down, it selectively targets the upstream signaling pathways that drive inflammatory cascades, allowing researchers to study immune modulation without wholesale immunosuppression.

KPV’s primary mechanism centers on inhibition of the NF-κB pathway — one of the master regulators of inflammatory cytokine production. Research has demonstrated that KPV acts intracellularly, entering cells via the PepT1 peptide transporter (which is upregulated in inflamed intestinal tissue), where it stabilizes IκBα and suppresses nuclear translocation of p65RelA, effectively blocking NF-κB activation at the nuclear import stage. This mechanism is independent of melanocortin receptor binding, distinguishing KPV from its parent molecule α-MSH.

Unlike corticosteroids or biologics, KPV modulates inflammation rather than suppressing it — making it particularly valuable for studying chronic inflammatory states where immune preservation is a research priority.

Research Applications

KPV is used in studies examining:

• Intestinal inflammation models, including colitis, IBD, Crohn’s disease, and ulcerative colitis pathways
• Epithelial barrier dysfunction and mucosal healing in the gut
• NF-κB and MAPK pathway inhibition under pro-inflammatory cytokine stimulation
• Wound healing dynamics in cutaneous and mucosal tissue models
• Antimicrobial activity against pathogens including S. aureus and C. albicans
• Airway epithelium inflammation and chemokine signaling in pulmonary disease models
• Comparative efficacy of targeted vs. broad-spectrum anti-inflammatory compounds

Specifications

Reconstitution

KPV arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example: 10mg vial + 2mL BAC water = 5mg/mL solution Example: 5mg vial + 1mL BAC water = 5mg/mL solution

Add bacteriostatic water slowly by angling the needle so liquid runs down the inside wall of the vial — do not inject directly onto the powder. Gently swirl to dissolve; do not shake, as this can degrade peptide structure. Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

KPV is studied across a range of doses depending on the research application. Due to its potency at nanomolar concentrations in vitro, precise measurement is essential. Subcutaneous injection is the most common route in systemic research models; oral administration is also used specifically in gut/intestinal studies, as KPV demonstrates notable stability in the GI tract.

Typical research dosing framework (injectable):

• Starting dose: 250–500mcg per administration
• Escalation: Increase by 250mcg increments based on experimental parameters
• Frequency: Once daily
• Study duration: 4–8 weeks depending on endpoint

Commonly observed effects in research models:

• Local (injection site): Mild redness, transient swelling, or irritation — generally self-resolving
• GI: Mild nausea or changes in bowel habits, particularly at higher experimental doses
• Other: Fatigue or headache noted anecdotally; no severe adverse effects identified in preclinical literature

Research Stacks

KPV is commonly paired in research settings with:

• BPC-157 — BPC-157 promotes mucosal repair and angiogenesis through NO-pathway and growth factor signaling, while KPV exerts anti-inflammatory effects via MC1R-mediated NF-κB suppression; the two are studied together in gut inflammation models for potentially complementary tissue-repair and immune-modulation activity.
• LL-37 — LL-37 is a host defense peptide with antimicrobial and immunomodulatory properties; pairing with KPV is studied in models where local immune dysregulation and barrier disruption co-occur, given that the two peptides operate through partially non-overlapping anti-inflammatory pathways.
• Thymosin Alpha-1 — Thymosin Alpha-1 activates innate immune signaling and dendritic cell maturation; combining it with KPV’s MC1R-mediated NF-κB suppression allows researchers to examine systemic immune activation alongside localized anti-inflammatory modulation.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.